Biomanufacturing the future
rBIO has developed a platform that can be leveraged to express a range of therapeutic polypeptides—starting with insulin.
Our recombinant expression platform is reshaping the way essential biologic drugs are made, with the goal of reducing insulin costs by 30% and reshoring crucial pharmaceutical production to the U.S.
The problem
Insulin isn’t just expensive, it’s vulnerable
Roughly 40 million Americans rely on insulin, but most of it is made overseas.
Recent manufacturer shifts and discontinuations are creating new risks for patients who depend on specific formulations.
At rBIO, we’re tackling this crisis with a scalable biosimilar insulin program built on a novel recombinant DNA platform that doubles current insulin yields.
12% of Americans live with diabetes
And yet just 21% of essential drug manufacturing facilities are located in the U.S.
We’re working to change that.
Our lead program: R-biolin™
R-biolin is a biosimilar insulin developed using rBIO’s proprietary expression platform. It has shown bioequivalence to Novolin® R in preclinical studies and is now being readied for clinical trials.
Validated via in vitro and in vivo studies
Scalable for industrial production
Designed to lower insulin costs by 30%
Our reprogrammed microorganisms manufacture life-saving drugs
rBIO’s platform uses advances in synthetic biology to express human proteins, including peptide hormones such as insulin.
This synthetic biology approach is faster, cheaper, and more adaptable than legacy methods.
America’s drug supply is a national security issue
The pandemic revealed the dangers of offshore dependencies.
We envision a new model that centers on domestic manufacturing, synthetic scalability, and public-private collaboration.
We’re not just making medicine.
